DOCSLIB.ORG

Phenyltoloxamine Citrate/Propiomazine 589 2

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Phenyltoloxamine Citrate/Propiomazine 589 2 Phenyltoloxamine Citrate/Propiomazine 589 2. Kahn A, Blum D. Phenothiazines and sudden infant death syn- Promethazine hydrochloride is used for the sympto- injection or injected into the tubing of a freely running drome. Pediatrics 1982; 70: 75–8. 3. Kahn A, et al. Phenothiazine-induced sleep apneas in normal in- matic relief of allergic conditions including urticaria infusion in a concentration of not more than fants. Pediatrics 1985; 75: 844–7. and angioedema (p.565), rhinitis (p.565) and conjunc- 25 mg/mL, although it is usually diluted to 2.5 mg/mL. 4. Cockfield. Phenergan, Theralene, Algotropyl—drugs responsi- ble for the death of new-born babies. Off J EC 1986; 29: tivitis (p.564), and in pruritic skin disorders (p.565). It The rate of infusion should not exceed 25 mg/minute. C130/25–6. may be given intravenously as an adjunct in the emer- The usual parenteral dose for all indications apart from 5. Stanton AN. Sudden infant death syndrome and phenothiazines. gency treatment of anaphylactic shock (p.563). nausea and vomiting is 25 to 50 mg; a dose of 100 mg Pediatrics 1983; 71: 986–7. Promethazine hydrochloride and promethazine teo- should not be exceeded. Doses of 12.5 to 25 mg, re- Precautions clate are used for their antiemetic action in the preven- peated at intervals of not less than 4 hours, may be giv- As for the sedating antihistamines in general, p.562. tion and treatment of nausea and vomiting in condi- en for the treatment of nausea and vomiting, although Intravenous injections of promethazine hydrochloride tions such as motion sickness, drug-induced vomiting, not more than 100 mg is usually given in 24 hours. must be given slowly and extreme care must be taken and postoperative vomiting (p.564). They are also used Children aged 5 to 10 years may be given 6.25 to to avoid extravasation or inadvertent intra-arterial in- for the symptomatic treatment of nausea and vertigo 12.5 mg of promethazine hydrochloride by deep intra- jection, because of the risk of severe irritation. Intra- caused by Ménière’s disease and other vestibular disor- muscular injection. muscular injection may be painful, and it should not be ders (see Vertigo, p.565). Promethazine hydrochloride Promethazine has been used topically to provide relief given by subcutaneous injection. is also employed pre- and postoperatively in surgery in hypersensitivity disorders of the skin and for burns False negative and positive results have been reported and obstetrics for its sedative effects and for the relief but, as with other antihistamines, it may produce skin with some pregnancy tests. of apprehension (see Anaesthesia, p.563); it is often sensitisation. given with pethidine hydrochloride. Promethazine hy- Anaesthesia. In 8 healthy subjects promethazine 25 mg intra- Sedation. For reference to the use of lytic cocktails of chlorpro- venously decreased lower oesophageal sphincter pressure and drochloride may be used for night-time sedation (see mazine, promethazine, and pethidine, and the view that alterna- increased the incidence of gastro-oesophageal reflux.1 It might, Insomnia, p.564). tives should be considered in children, see under Pethidine, therefore, increase the risk of regurgitation and aspiration of gas- Promethazine hydrochloride is a common ingredient p.115. tric contents during induction of and recovery from anaesthesia. of compound preparations for the symptomatic treat- Preparations The effect was attributed to the antimuscarinic properties of pro- methazine. ment of coughs and the common cold (p.564). BP 2008: Promethazine Hydrochloride Tablets; Promethazine Injection; Promethazine Oral Solution; Promethazine Teoclate Tablets; 1. Brock-Utne JG, et al. The action of commonly used antiemetics The following doses have been given orally. USP 31: Promethazine Hydrochloride Injection; Promethazine Hydrochlo- on the lower oesophageal sphincter. Br J Anaesth 1978; 50: ride Suppositories; Promethazine Hydrochloride Syrup; Promethazine Hy- 295–8. • For the treatment of allergic conditions promethaz- ine hydrochloride is usually given in a dose of 25 mg drochloride Tablets. Children. A possible association between phenothiazine seda- Proprietary Preparations (details are given in Part 3) tives and sudden infant death syndrome has been suggested, but at night increased to 25 mg twice daily if necessary; Arg.: Fenergan; Austral.: Avomine; Gold Cross Antihistamine Elixir†; In- has not been confirmed (see under Adverse Effects, above). The owing to its pronounced sedative effect it is prefera- somn-Eze†; Nyal Plus+ Allergy Relief†; Phenergan; Belg.: Phenergan; Braz.: Alergiderm; Alergosan†; Fenergan; Pamergan; Profergan; Prometa- current view in the UK and USA is that promethazine should not bly given at night but an alternative dose is 10 to zol; Canad.: Histantil; Phenergan†; Cz.: Prothazin; Denm.: Phenergan; Fr.: be given to children under 2 years of age. 20 mg two or three times daily. Phenergan; Ger.: Atosil; Closin; Eusedon mono†; Promethawern†; Prone- urin; Prothanon; Gr.: Phenergan; Titanox; Hong Kong: Anvomin; Fenazin; Porphyria. Promethazine is considered to be unsafe in patients • Promethazine hydrochloride is given in doses of 20 Synvomin; Hung.: Pipolphen; India: Avomine; Emin; Phenergan; Indon.: with porphyria because it has been shown to be porphyrinogenic Nufapreg; Phenergan; Irl.: Phenergan; Israel: Prothiazine; Ital.: Allerfen†; in animals or in-vitro systems. to 50 mg at night for the short-term management of Fargan; Farganesse; Fenazil; Malaysia: Prothazine†; Norw.: Phenergan; insomnia although its prolonged duration of action NZ: Allersoothe; Avomine; Phenergan; Philipp.: Zinmet; Pol.: Diphergan; Pregnancy. For discussion of the use of antihistamines in preg- Port.: Fenergan; Rus.: Pipolphen (Пипольфен); S.Afr.: Avomine; Bruna- nancy, including studies involving phenothiazines, see p.563. can lead to considerable drowsiness the following zine; Daralix; Lenazine; Phenergan; Prohist; Receptozine; Spain: Fenergan day. Topico; Frinova; Swed.: Lergigan; Thai.: Meta; Phenergan; Titanox†; UAE: Renal impairment. Phenothiazine-induced toxic psychosis Histaloc; UK: Avomine; Phenergan; Sominex; Ziz; USA: Phenadoz; Phener- occurred in a patient with chronic renal failure who had been giv- • For the prevention of motion sickness promethazine gan; Promethegan; Venez.: Diven†; Fenergan†. en promethazine.1 hydrochloride can be given in a dose of 20 or 25 mg Multi-ingredient: Austral.: Painstop; Painstop Night-Time Pain Reliever; 1. McAllister CJ, et al. Toxic psychosis induced by phenothiazine the night before travelling followed by a similar dose Panquil; Phensedyl†; Tixylix Nightime; Braz.: Dorilen; Doriless; Fenergan administration in patients with chronic renal failure. Clin Neph- Expectorante; Lisador; Canad.: Promatussin DM†; Cz.: Coldrex Nite; Fr.: the following morning if necessary. The teoclate is Algotropyl†; Fluisedal; Rhinathiol Promethazine; Transmer†; Tussisedal; rol 1978; 10: 191–5. Ger.: Prothazin; Hong Kong: Dhasedyl; Ephedyl; Fendyl; Marsedyl; Meth- used similarly. For the prevention of motion sickness orsedyl; PEC; Phensedyn; Procodine†; Promethazine Compound Linctus†; Interactions the dose of promethazine teoclate is 25 mg at night Rhinathiol Promethazine; Super Cough†; Tripe P; Hung.: Tar dyl†; India: Tixylix; Indon.: Berlifed; Fludexin; Halmezin; Neo Davenol; Phenadex; As for the sedating antihistamines in general, p.563. or 25 mg one to two hours before travelling. Prome; Promedex; Promethazine Ikapharmindo; Irl.: Night Nurse; Israel: • For nausea and vomiting arising from causes such as Promethazine Expectorants; Prothiazine Expectorant; Ital.: Bronconait†; Nuleron; Tachinotte; Malaysia: Axcel Dextrozine; Dextrodyl; Dex- Pharmacokinetics labyrinthitis a dose of promethazine teoclate 25 mg tromethorphan Compound; Dhasedyl DM; Hosedyl DM; Mucoease Plus; Promethazine is well absorbed after oral or intramus- Phensedyl Dry Cough; Phensedyl†; Promedyl†; Rhinathiol Promethazine; at night is usually adequate; this may be increased to Russedyl Plus; Russedyl†; SCMC Promethazine†; Sedilix DM†; Sedilix†; Tix- cular doses. Peak plasma concentrations have been 50 or 75 mg at night or to 25 mg two or three times ylix†; NZ: Phensedyl Dry Family Cough†; Tixylix; Rus.: Prothiazine Expec- seen 2 to 3 hours after a dose by these routes, although torant (Протиазин Экспекторант); S.Afr.: Acustop; Adco-Kiddipayne; daily if necessary to a maximum of 100 mg daily. Antipyn†; Ban Pain; Brunacod; Colcaps; Dequa-Coff; Fevapar; Go-Pain; there is low systemic bioavailability after oral doses, •For severe vomiting in pregnancy the BNF recom- Goldgesic†; Histodor; Infacet; Infapain Forte; Kid-Eeze; Lenazine Forte; Len- due to high first-pass metabolism in the liver. Promet- togesic; Lesspain†; Medipyn; Megapyn; Mepromol; Painagon; Pedpain; mends a dose of promethazine teoclate 25 mg at Phensedyl; Propain†; Pynmed; Salterpyn; Stilpane; Stopayne; Tenston; Tixy- hazine crosses the blood-brain barrier and the placenta, night, increased if necessary to a maximum of lix; Vacudol; Xeramax†; Singapore: Beacodyl; Cophadyl; Cophadyl-E; and is distributed into breast milk. Values ranging from Dhasedyl; Dhasedyl DM; PCL†; Phensedyl†; Procodin; Promedyl†; Rhinath- 100 mg. iol Promethazine; Sedilix; Sedilix DM; Unisedyl†; Spain: Actithiol Antihist; 76 to 93% have been reported for plasma-protein bind- In children the following oral doses of promethazine Antihemorroidal†; Fenergan Expectorante; Psicosoma Solucion; Swed.: ing. Promethazine undergoes extensive
Load more

Recommended publications
  • Determination of Quifenadine by HPLC Method in Blood
    ISSN 2311-715X (Print) Український біофармацевтичний журнал, № 3 (64) 2020 ISSN 2519-8750 (Online) UDC 615.218:001.891:543.42:543.544 https://doi.org/10.24959/ubphj.20.277 O.National Mamina, University V. Kabachny, of Pharmacy O. Lozova* of the Ministry of Health of Ukraine * Private Higher Educational Institution “Kyiv Medical University” determination of quifenadine by HPLC method in blood Topicality. - tion H1-histamine receptor blocker. The drug reduces the content of histamine in tissues due to the activation of the enzyme Quifenadine hydrochloride (phencarol) – quinuclidinyl-3-diphenyl carbinol hydrochloride – first genera- diamine oxidase, which breaks down up to 30 % of tissue histamine. Quifenadine hydrochloride is superior to diphenhy dramine in duration of antihistamine action. Unlike diphenhydramine and diprazine, quifenadine does not inhibit the CNS, is characterized by weak sedative properties. Quifenadine hydrochloride can be used in the development of tolerance to other sedative antihistamines. Quifenadine hydrochloride is used to treat anaphylactic shock, urticaria, hay fever, Quincke’s edema, dermatoses, allergic rhinitis, food and drug allergies. In case of overdose of quifenadine hydrochloride- chloridecauses dryness in pharmaceuticals of the mucous and membranes, biological headache, matrices duringvomiting, treatment stomach are pain based and dyspepsia.on the choice At highof highly doses, sensitive it can affect and the cardiovascular system, gastrointestinal tract, liver and kidneys. Detection and quantification of quifenadine hydro antihistamines and diagnosis of drug intoxication. selectiveAim. research methods, which is an urgent task for monitoring the effectiveness of treatment of the population with Materials To develop and methods. an algorithm for directed analysis of quifenadine in biological extracts from blood using a unified method of HPLC research.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Pharmacology on Your Palms CLASSIFICATION of the DRUGS
    Pharmacology on your palms CLASSIFICATION OF THE DRUGS DRUGS FROM DRUGS AFFECTING THE ORGANS CHEMOTHERAPEUTIC DIFFERENT DRUGS AFFECTING THE NERVOUS SYSTEM AND TISSUES DRUGS PHARMACOLOGICAL GROUPS Drugs affecting peripheral Antitumor drugs Drugs affecting the cardiovascular Antimicrobial, antiviral, Drugs affecting the nervous system Antiallergic drugs system antiparasitic drugs central nervous system Drugs affecting the sensory Antidotes nerve endings Cardiac glycosides Antibiotics CNS DEPRESSANTS (AFFECTING THE Antihypertensive drugs Sulfonamides Analgesics (opioid, AFFERENT INNERVATION) Antianginal drugs Antituberculous drugs analgesics-antipyretics, Antiarrhythmic drugs Antihelminthic drugs NSAIDs) Local anaesthetics Antihyperlipidemic drugs Antifungal drugs Sedative and hypnotic Coating drugs Spasmolytics Antiviral drugs drugs Adsorbents Drugs affecting the excretory system Antimalarial drugs Tranquilizers Astringents Diuretics Antisyphilitic drugs Neuroleptics Expectorants Drugs affecting the hemopoietic system Antiseptics Anticonvulsants Irritant drugs Drugs affecting blood coagulation Disinfectants Antiparkinsonian drugs Drugs affecting peripheral Drugs affecting erythro- and leukopoiesis General anaesthetics neurotransmitter processes Drugs affecting the digestive system CNS STIMULANTS (AFFECTING THE Anorectic drugs Psychomotor stimulants EFFERENT PART OF THE Bitter stuffs. Drugs for replacement therapy Analeptics NERVOUS SYSTEM) Antiacid drugs Antidepressants Direct-acting-cholinomimetics Antiulcer drugs Nootropics (Cognitive
    [Show full text]
  • Examination Questions
    EXAMINATION QUESTIONS CHAPTER I. GENERAL PHARMACOLOGY AND PRESCRIPTION 1. Essence of pharmacology as a science. Parts and fields of modern pharmacology. The main terms and concepts of pharmacology – pharmacological activity, action, efficiency. 2. Sources and stages of drug development. Drugs – generics, placebo effects. Definition of such concepts as medicinal agent (medicinal drug, drug), medicinal substance, medicinal form. 3. Routes of drug administration into the body and their characteristic. Presystemic drug elimination. 4. Drug transfer through biological barriers and their types. The main factors influencing on the drug transfer in the body. 5. Drug transfer of variable ionization substances through membranes (Henderson-Hasselbach's equation of ionization). Principles of transfer management. 6. Drug transfer in the body. Aqueous diffusion and lipid diffusion (Fick's diffusion equation). Active transport. 7. Central postulate of pharmacokinetics: concentration of medicinal substance in blood plasma – the main parameter for management of the pharmacological effect. The tasks solved on the basis of this postulate. 8. Pharmacokinetic models (one-compartment and two-compartment), quantitative laws of absorption and drug elimination. 9. Bioavailability of drugs – definition, essence, quantitative expression, determinants. 10. Drug distribution in the body: compartments, ligands, the main determinants of distribution. 11. Elimination rate constant, its essence, dimension, connection with other pharmacokinetic parameters. 12. Excretion half-life of drugs, its essence, dimension, connection with other pharmacokinetic parameters. 13. Clearance as the main parameter of pharmacokinetics for management of the dosing regimen. Its essence, dimension and connection with other pharmacokinetic parameters. 14. Dose. Types of doses. Units of drug dosage. Aims of drug dosage, ways and variants of administration of drugs, dosing interval.
    [Show full text]
  • Profile Profile Profile Profile Uses and Administration Adverse Effects And
    640 Antihistamines Propiomazine Hydrochloride {BANM, r!NNMJ P..r�p�rc:Jti()n.� ............................ m (details are given in Volume B) propiorf,azina; to o azine; Chiorhydrate ProprietaryPreparations HidrodoruroPropi<;>rn deazini HydrochloridP pium; f1ponvtot,la3Y!Ha China: Qi Qi Hung. : de; Single-ingredient Preparafions. Loderixt. CIH'f); rMAPOX!10p!'\A. C;cJcl1_,--N_,QS,HCI�3.76_91 Rupatadine is an antihistamine with platelet-activating CAS 240) 5-9. factor (PAF) antagonist activity that is used for the Terfenadine (BAN, USAN, r!NN) treatment of allergic rhinitis (p. 612.1) and chronic 1 idiopathic urticaria (p. 612.3). It is given as the fumarate although doses are expressed in terms of the base; rupatadine fumarate 12.8 mg is equivalent to about 10 mg of rupatadine. The usual oral dose is the equivalent of 10 mg once daily of rupatadine. Izquierdo I. et a!. Rupatadine: a new selective histamine HI receptor and platelet-activating factor (PAF) antagonist: a review of pharmacological profile and clinical management of allergic rhinitis. Drugs Today 2003; 39: 451-68. 2. Kearn SJ,Plosker GL. Rupatadine: a review of its use in the management of allergic disorders. Drugs 2007; 67: 457-74. 3. Fantin et at. International Rupatadine study group. A 12-week 5, 8: (Terfenadine). A white or almost white, placebo-controlled study of rupatadine 10 mg once daily compared with Ph. Bur. cetirizine IO mg once daily, in the treatment of persistent allergic crystalline powder. It shows polymorphism. Very slightly rhinitis. Allergy 2008; 63: 924-3 1. soluble in water and in dilute hydrochloric acid; freely 4.
    [Show full text]
  • Quifenadine Hydrochloride/Thiethylperazine 591 Breast Milk; Its Active Metabolite, Fexofenadine, Was Excreted in 2
    Quifenadine Hydrochloride/Thiethylperazine 591 breast milk; its active metabolite, fexofenadine, was excreted in 2. Honig P, et al. Effect of erythromycin, clarithromycin and azi- rhinitis (p.565) and conjunctivitis (p.564) and skin disorders such limited amounts. thromycin on the pharmacokinetics of terfenadine. Clin Pharma- as urticaria (p.565). col Ther 1993; 53: 161. 1. American Academy of Pediatrics. The transfer of drugs and oth- 3. Biglin KE, et al. Drug-induced torsades de pointes: a possible The maximum oral dose of terfenadine is 120 mg daily given ei- er chemicals into human milk. Pediatrics 2001; 108: 776–89. interaction of terfenadine and erythromycin. Ann Pharmacother ther as 60 mg twice daily or 120 mg in the morning; a starting Correction. ibid.; 1029. Also available at: 1994; 28: 282. dose of 60 mg daily in a single dose or in two divided doses is http://aappolicy.aappublications.org/cgi/content/full/ 4. Fournier P, et al. Une nouvelle cause de torsades de pointes: as- pediatrics%3b108/3/776 (accessed 08/04/04) recommended for rhinitis and conjunctivitis. Children who are sociation terfenadine et troleandomycine. Ann Cardiol Angeiol over 12 years of age and weigh more than 50 kg may receive the 2. Lucas BD, et al. Terfenadine pharmacokinetics in breast milk in (Paris) 1993; 42: 249–52. lactating women. Clin Pharmacol Ther 1995; 57: 398–402. usual adult dosage. Antidepressants. Cardiac abnormalities have been reported in For dosage in renal impairment see below. Effects on the liver. Three episodes of acute hepatitis with 2 patients taking fluoxetine with terfenadine.1,2 Similarly, the use jaundice occurred in a patient taking terfenadine intermittently Administration in renal impairment.
    [Show full text]
  • The Use of Central Nervous System Active Drugs During Pregnancy
    Pharmaceuticals 2013, 6, 1221-1286; doi:10.3390/ph6101221 OPEN ACCESS pharmaceuticals ISSN 1424-8247 www.mdpi.com/journal/pharmaceuticals Review The Use of Central Nervous System Active Drugs During Pregnancy Bengt Källén 1,*, Natalia Borg 2 and Margareta Reis 3 1 Tornblad Institute, Lund University, Biskopsgatan 7, Lund SE-223 62, Sweden 2 Department of Statistics, Monitoring and Analyses, National Board of Health and Welfare, Stockholm SE-106 30, Sweden; E-Mail: [email protected] 3 Department of Medical and Health Sciences, Clinical Pharmacology, Linköping University, Linköping SE-581 85, Sweden; E-Mail: [email protected] * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +46-46-222-7536, Fax: +46-46-222-4226. Received: 1 July 2013; in revised form: 10 September 2013 / Accepted: 25 September 2013 / Published: 10 October 2013 Abstract: CNS-active drugs are used relatively often during pregnancy. Use during early pregnancy may increase the risk of a congenital malformation; use during the later part of pregnancy may be associated with preterm birth, intrauterine growth disturbances and neonatal morbidity. There is also a possibility that drug exposure can affect brain development with long-term neuropsychological harm as a result. This paper summarizes the literature on such drugs used during pregnancy: opioids, anticonvulsants, drugs used for Parkinson’s disease, neuroleptics, sedatives and hypnotics, antidepressants, psychostimulants, and some other CNS-active drugs. In addition to an overview of the literature, data from the Swedish Medical Birth Register (1996–2011) are presented. The exposure data are either based on midwife interviews towards the end of the first trimester or on linkage with a prescribed drug register.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]
  • Drugs and Medication Guidelines Brochure
    Equine Medication Monitoring Program Drugs and Medication Guidelines January 2021 1 Introduction The California Equine Medication Monitoring Program (EMMP) is an industry funded program to ensure the integrity of public equine events and sales in California through the control of performance and disposition enhancing drugs and permitting limited therapeutic use of drugs and medications. The EMMP and the industry is dedicated and committed to promote the health, welfare and safety of the equine athlete. Owners, trainers, exhibitors, veterinarians and consignors of equines to public sales have a responsibility to be familiar with the California EMMP and the California Equine Medication Rule. California law (Food and Agricultural Code Sections 24000-24018) outlines the equine medication rule for public equine events in California. The owner, trainer and consignor have responsibility to ensure full compliance with all elements of the California Equine Medication Rule. Owners, trainers, exhibitors, veterinarians and consignors of equines to public sales must comply with both the California Equine Medication Rule and any sponsoring organization drug and medication rule for an event. The more stringent medication rule applies for the event. The California Equine Medication Rule is posted on the website: http://www.cdfa.ca.gov/ahfss/Animal_Health/emmp/ The information contained in this document provides advice regarding the California Equine Medication Rule and application of the rule to practical situations. The EMMP recognizes that situations arise where there is an indication for legitimate therapeutic treatment near the time of competition at equine events. The EMMP regulations permit the use of therapeutic medication in certain circumstances to accommodate legitimate therapy in compliance with the requirements of the rule.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • WHO Drug Information Vol
    WHO Drug Information Vol. 26, No. 4, 2012 WHO Drug Information Contents International Regulatory Regulatory Action and News Harmonization New task force for antibacterial International Conference of Drug drug development 383 Regulatory Authorities 339 NIBSC: new MHRA centre 383 Quality of medicines in a globalized New Pakistan drug regulatory world: focus on active pharma- authority 384 ceutical ingredients. Pre-ICDRA EU clinical trial regulation: public meeting 352 consultation 384 Pegloticase approved for chronic tophaceous gout 385 WHO Programme on Tofacitinib: approved for rheumatoid International Drug Monitoring arthritis 385 Global challenges in medicines Rivaroxaban: extended indication safety 362 approved for blood clotting 385 Omacetaxine mepesuccinate: Safety and Efficacy Issues approved for chronic myelo- Dalfampridine: risk of seizure 371 genous leukaemia 386 Sildenafil: not for pulmonary hyper- Perampanel: approved for partial tension in children 371 onset seizures 386 Interaction: proton pump inhibitors Regorafenib: approved for colorectal and methotrexate 371 cancer 386 Fingolimod: cardiovascular Teriflunomide: approved for multiple monitoring 372 sclerosis 387 Pramipexole: risk of heart failure 372 Ocriplasmin: approved for vitreo- Lyme disease test kits: limitations 373 macular adhesion 387 Anti-androgens: hepatotoxicity 374 Florbetapir 18F: approved for Agomelatine: hepatotoxicity and neuritic plaque density imaging 387 liver failure 375 Insulin degludec: approved for Hypotonic saline in children: fatal diabetes mellitus
    [Show full text]